Mabwell is a Shanghai-based, innovation-driven biopharmaceutical company founded in 2017, with a full “lab-to-market” infrastructure that integrates discovery, preclinical research, manufacturing, and commercialization. The company focuses on next-generation antibody therapeutics across areas such as oncology, immunology, bone disorders, ophthalmology, and age-related diseases. It has 16 pipeline candidates, including both novel biologics and biosimilars, with four products already approved and another in pivotal trials. Mabwell is supported by high-throughput drug discovery platforms and GMP-compliant production facilities in China, the U.S., and Europe.